MGC Pharmaceuticals Ltd (ASX: MXC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
MGC Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
MGC Pharmaceuticals Ltd (ASX: MXC)
Latest News
Healthcare Shares
The MGC Pharmaceuticals (ASX:MXC) share price soared 20% today. Here's why
Healthcare Shares
MGC Pharmaceuticals (ASX:MXC) share price climbs on study approval
Healthcare Shares
Why the MGC Pharmaceuticals (ASX:MXC) share price is leaping 5%
Share Market News
What's going wrong for ASX cannabis shares lately?
Share Gainers
MGC Pharma (ASX:MXC) share price jumps 11% on UK approval
Share Market News
MGC Pharmaceuticals (ASX:MXC) share price rockets 40% on supply deal
Healthcare Shares
The MGC Pharmaceuticals (ASX:MXC) share price is on a roll today. Here's why
Share Gainers
Why the MGC Pharma (ASX:MXC) share price has rocketed 9%
Healthcare Shares
Why the MGC Pharmaceuticals (ASX:MXC) share price is up 5% today
Share Market News
Why the MGC Pharma (ASX:MXC) share price is zooming 13% higher today
Share Market News
Why the MGC Pharmaceuticals (ASX:MXC) share price is jumping 8%
Share Market News
Up 310% the MGC Pharma (ASX:MXC) share price is gaining again today
MXC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About MGC Pharmaceuticals Ltd
MGC Pharmaceuticals Ltd is a biopharma company with a Nature to Medicine strategy at the forefront of the emerging phytocannabinoid and plant-derived medicine markets. The company's mission is to build an innovative, global bio-pharma company providing standardized, affordable plant-derived medicines of the highest regulatory compliance for targeted global markets.
MXC Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
28 Mar 2024 | $0.41 | $-0.01 | -2.38% | 9,618 | $0.41 | $0.41 | $0.40 |
27 Mar 2024 | $0.42 | $0.03 | 7.59% | 13,088 | $0.40 | $0.42 | $0.40 |
26 Mar 2024 | $0.40 | $-0.02 | -4.88% | 38,947 | $0.41 | $0.41 | $0.39 |
25 Mar 2024 | $0.41 | $-0.03 | -6.90% | 1,435 | $0.44 | $0.44 | $0.41 |
22 Mar 2024 | $0.44 | $0.00 | 0.00% | 2,710 | $0.44 | $0.44 | $0.41 |
21 Mar 2024 | $0.44 | $0.01 | 2.33% | 25,204 | $0.43 | $0.44 | $0.43 |
20 Mar 2024 | $0.43 | $0.02 | 4.88% | 11,514 | $0.43 | $0.43 | $0.41 |
19 Mar 2024 | $0.41 | $-0.01 | -2.38% | 43 | $0.42 | $0.42 | $0.41 |
18 Mar 2024 | $0.42 | $-0.02 | -4.60% | 1,040 | $0.44 | $0.44 | $0.42 |
15 Mar 2024 | $0.44 | $0.03 | 7.32% | 5,114 | $0.42 | $0.44 | $0.42 |
14 Mar 2024 | $0.41 | $0.00 | 0.00% | 10,067 | $0.41 | $0.43 | $0.41 |
13 Mar 2024 | $0.41 | $-0.01 | -2.38% | 86,359 | $0.41 | $0.42 | $0.41 |
12 Mar 2024 | $0.42 | $0.00 | 0.00% | 102,188 | $0.42 | $0.42 | $0.40 |
11 Mar 2024 | $0.42 | $-0.01 | -2.35% | 17,054 | $0.43 | $0.43 | $0.40 |
08 Mar 2024 | $0.43 | $-0.01 | -2.33% | 65,674 | $0.43 | $0.43 | $0.41 |
07 Mar 2024 | $0.43 | $-0.02 | -4.44% | 6,201 | $0.45 | $0.45 | $0.43 |
06 Mar 2024 | $0.45 | $-0.05 | -10.00% | 86,357 | $0.45 | $0.45 | $0.43 |
05 Mar 2024 | $0.50 | $0.08 | 19.05% | 133,054 | $0.42 | $0.50 | $0.42 |
04 Mar 2024 | $0.42 | $-0.03 | -6.67% | 36,052 | $0.44 | $0.50 | $0.42 |
01 Mar 2024 | $0.45 | $0.00 | 0.00% | 60,235 | $0.45 | $0.45 | $0.41 |
29 Feb 2024 | $0.45 | $0.05 | 12.50% | 13,116 | $0.40 | $0.45 | $0.40 |
28 Feb 2024 | $0.40 | $0.03 | 8.00% | 19,552 | $0.38 | $0.40 | $0.38 |
27 Feb 2024 | $0.38 | $-0.04 | -9.76% | 16,733 | $0.41 | $0.41 | $0.38 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
05 May 2023 | Brett Mitchell | Expiry | 17,500,000 | $157,500 |
As advised by the company. 49,00,000 Performance Rights, As per announcement on 05-05-2023
|
05 May 2023 | Ross Walker | Expiry | 1,050,000 | $9,450 |
As advised by the company. Lapse of Performance Rights
|
05 May 2023 | Nativ Segev | Expiry | 1,050,000 | $9,450 |
As advised by the company. 600,000 Performance Rights, AS per announcement on 05-05-2023
|
05 May 2023 | Roby Zomer | Expiry | 17,500,000 | $157,500 |
As advised by the company. 49,00,000 Performance Rights, As per announcement on 05-05-2023
|
05 May 2023 | Stephen Parker | Expiry | 1,400,000 | $12,600 |
As advised by the company. Lapse of Performance Rights, As per announcement on 05-05-2023
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Layton Patrick Mills | Non-Executive Director | Jun 2023 |
Mr Mills is a life-sciences executive, having worked in the biotechnology and life sciences industries for over 15 years, developing experience across human and animal health in pharmaceutical and consumer healthcare.
|
Mr Brett Anthony Mitchell | Executive ChairmanExecutive Director | Apr 2013 |
Mr Mitchell has over 25 years of experience in the venture capital, equity capital markets, technology and resources sectors. He has been involved in the founding, financing and management of both private and publicly listed companies, and was instrumental in the successful LSE listing for MGC Pharma in February 2021.
|
Mr Daniel Robinson | Non-Executive Director | Dec 2023 |
Mr Robinson has 20 years experience in a range of corporate roles across stockbroking, corporate advisory, investor relations and governance. He is a Company Secretary and Director of both private and listed companies.
|
Mr Nativ Segev | Non-Executive Director | Feb 2016 |
Mr Segev has over 10 years of experience in implementation, legislation and lobbying in the global Medical Cannabis industry, combined with over 15 years of experience in diverse executive roles.
|
Mr Roby Reuven Zomer | Chief Executive OfficerManaging Director | Feb 2016 |
Mr Zomer was recruited into MGC Pharma by its founders at the inception of the company and has since served in multiple roles within the company, culminating with his current role as MD and CEO. With 11 years of experience in projects in the Biotech and Agrotech sectors, Mr Zomer has been necessary in moving MGC Pharma from a cannabis concept to a fully functioning biopharma company with global activities.
|
Mr Messrs Rowan Harland | Company Secretary | Mar 2023 |
-
|
Messrs Rowan Harland | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Computershare Clearing Pty Ltd <Ccnl Di A/C> | 1,416,661,256 | 31.99% |
Bioheka Limited | 107,000,000 | 2.42% |
Citicorp Nominees Pty Limited | 95,516,192 | 2.16% |
Orca Capital Gmbh | 94,287,918 | 2.13% |
Hsbc Custody Nominees (Australia) Limited | 93,845,701 | 2.12% |
BNP Paribas Nominees Pty Ltd Acf Clearstream | 85,199,520 | 1.92% |
Mr Shachar Shimony | 69,500,000 | 1.57% |
Mercer Street Global Opportunity Fund Llc | 65,600,000 | 1.48% |
Sofia Even | 51,000,000 | 1.15% |
Mr Michael Sean Newton | 48,000,000 | 1.08% |
Chetcuti Holdings Pty Ltd | 46,044,900 | 1.04% |
Mr George Bishay | 36,822,890 | 0.83% |
Bnp Paribas Noms Pty Ltd <Drp> | 36,108,923 | 0.82% |
Mrs Ilena Alemao | 23,343,478 | 0.53% |
Mrs Yifat Steuer | 17,193,146 | 0.39% |
Fairbrother Holdings Pty Ltd | 16,043,478 | 0.36% |
Jep Pty Ltd <Jp Pension Fund A/C> | 13,675,805 | 0.31% |
Ibi Trust Management <Nadya Lisovoder A/C> | 13,372,365 | 0.31% |
Mr Gagandeep Singh | 13,333,333 | 0.30% |
Mr Paul Merlo | 13,043,488 | 0.29% |